以血卟啉衍生物(HpD)—激光治疗恶性肿瘤的先驱者是Dougherty等,用此法诊治人类癌症的第一例则是1976年报告的膀胱癌。Kinsey,Doiron,早田义博等均报告了在纤持支气管镜下以血卟啉萤光作早期肺癌的定位诊断。之后,早田义博、Corte—se、Balchum等又报告了以HpD—激光治疗肺癌。本疗法的基础是HpD对恶性肿瘤比正常组织有强得多的亲和力;HpD被405nm波长的紫光照射能产生630nm波长的红 The pioneer of hematoporphyrin derivative (HpD)-laser treatment of malignant tumors is Dougherty et al. The first case of diagnosis and treatment of human cancer using this method was bladder cancer as reported in 1976. Kinsey, Doiron, Yoshihiro Okada et al. reported the use of hematoporphyrin fluorescence for the early diagnosis of lung cancer under fiberbronchoscopes. Later, Yoshihiro Okada, Corte-se, Balchum, and others reported using HpD-laser to treat lung cancer. The basis of this therapy is that HpD has a much stronger affinity for malignant tumors than normal tissues; HpD is irradiated with violet light at a wavelength of 405nm to produce a red wavelength of 630nm.